Anika Therapeutics, Inc.
General ticker "ANIK" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $185.7M (TTM average)
Anika Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -18.8%.
Estimated limits based on current volatility of 1.2%: low 9.34$, high 9.57$
Factors to consider:
- Total employees count: 288 (-18.2%) as of 2024
- US accounted for 68.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on sales growth, Supply chain disruptions, Operational and conduct risks, Labor/talent shortage/retention, Strategic risks and growth management
- Current price 13.8% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [10.96$, 23.23$]
- 2025-12-31 to 2026-12-31 estimated range: [10.80$, 22.48$]
Financial Metrics affecting the ANIK estimates:
- Negative: with PPE of -38.8 at the end of fiscal year the price was high
- Positive: -5.02 < Operating profit margin, % of -4.08
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 75.95 > 64.17
- Negative: Investing cash flow per share per price, % of -3.47 <= -0.62
Short-term ANIK quotes
Long-term ANIK plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $113.83MM | $120.79MM | $119.91MM |
| Operating Expenses | $110.16MM | $119.95MM | $125.01MM |
| Operating Income | $3.67MM | $0.84MM | $-5.10MM |
| Non-Operating Income | $0.65MM | $2.31MM | $2.34MM |
| R&D Expense | $18.32MM | $21.76MM | $25.54MM |
| Income(Loss) | $4.32MM | $3.16MM | $-2.76MM |
| Taxes | $2.12MM | $6.59MM | $6.06MM |
| Other Income(Loss) | $-17.06MM | $-79.23MM | $-47.56MM |
| Profit(Loss)* | $-31.92MM | $-161.90MM | $-103.94MM |
| Stockholders Equity | $285.56MM | $212.26MM | $153.99MM |
| Inventory | $39.77MM | $24.43MM | $23.81MM |
| Assets | $349.13MM | $270.63MM | $202.74MM |
| Operating Cash Flow | $4.41MM | $-1.79MM | $5.40MM |
| Capital expenditure | $7.49MM | $5.43MM | $7.73MM |
| Investing Cash Flow | $-7.49MM | $-5.43MM | $-8.33MM |
| Financing Cash Flow | $-4.85MM | $-6.32MM | $-12.73MM |
| Earnings Per Share** | $-2.19 | $-11.05 | $-7.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.